-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Procaps Group (NASDAQ:PROC) Shares Gap Up to $4.73
Procaps Group (NASDAQ:PROC) Shares Gap Up to $4.73
Procaps Group S.A. (NASDAQ:PROC – Get Rating) shares gapped up before the market opened on Thursday . The stock had previously closed at $4.73, but opened at $5.15. Procaps Group shares last traded at $5.13, with a volume of 300 shares trading hands.
Procaps Group Trading Up 5.7 %
The stock's 50-day moving average is $6.10 and its 200 day moving average is $7.08.
Get Procaps Group alerts:Procaps Group (NASDAQ:PROC – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. The firm had revenue of $110.40 million for the quarter, compared to the consensus estimate of $123.90 million. As a group, equities analysts anticipate that Procaps Group S.A. will post 0.12 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PROC. Millennium Management LLC grew its position in Procaps Group by 15.9% during the second quarter. Millennium Management LLC now owns 101,430 shares of the company's stock valued at $945,000 after purchasing an additional 13,908 shares in the last quarter. Citadel Advisors LLC bought a new stake in Procaps Group in the second quarter worth approximately $263,000. Finally, State Street Corp bought a new stake in Procaps Group in the third quarter worth approximately $89,000. 0.95% of the stock is owned by hedge funds and other institutional investors.About Procaps Group
(Get Rating)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
Featured Articles
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- Why Did the JinkoSolar Stock Price Rally 45%?
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.
Procaps Group S.A. (NASDAQ:PROC – Get Rating) shares gapped up before the market opened on Thursday . The stock had previously closed at $4.73, but opened at $5.15. Procaps Group shares last traded at $5.13, with a volume of 300 shares trading hands.
Procaps Group S.A.(纳斯达克股票代码:PROC — Get Rating)的股价在周四开盘前跳空了。该股此前收于4.73美元,但开盘价为5.15美元。Procaps Group股票最后一次交易价格为5.13美元,交易量为300股。
Procaps Group Trading Up 5.7 %
Procaps 集团交易价格上涨5.7%
The stock's 50-day moving average is $6.10 and its 200 day moving average is $7.08.
该股的50天移动平均线为6.10美元,其200天移动平均线为7.08美元。
Procaps Group (NASDAQ:PROC – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. The firm had revenue of $110.40 million for the quarter, compared to the consensus estimate of $123.90 million. As a group, equities analysts anticipate that Procaps Group S.A. will post 0.12 EPS for the current fiscal year.
Procaps集团(纳斯达克股票代码:PROC — Get Rating)上次公布季度收益数据是在11月14日星期一。该公司公布的本季度每股收益为0.22美元,比分析师普遍预期的0.13美元高出0.09美元。Procaps集团的净利润率为13.82%,负股本回报率为243.60%。该公司本季度的收入为1.104亿美元,而市场普遍预期为1.239亿美元。作为一个集团,股票分析师预计,Procaps Group S.A. 将在本财年公布每股收益0.12。
Institutional Inflows and Outflows
机构流入和流出
About Procaps Group
关于 Procaps 集团
(Get Rating)
(获取评分)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
Procaps Group SA在全球范围内开发、生产和销售药品解决方案。该公司在各个治疗领域配制、制造和销售品牌处方药,包括女性护理产品、止痛药、皮肤护理、消化系统健康、生长发育、心脏病学、视力保健、中枢神经系统和呼吸系统。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- Why Did the JinkoSolar Stock Price Rally 45%?
- 免费获取 StockNews.com 关于 Procaps Group (PROC) 的研究报告的副本
- 阿里巴巴的大复苏即将开始吗?
- KB Home,抛售房屋建筑股票的另一个理由
- 温迪的股票上涨趋势会继续吗?
- 奥驰亚集团股票,时间不多了吗?
- 为什么晶科能源股价上涨了45%?
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Procaps 集团的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Procaps Group及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧